Inotiv Management
Management criteria checks 2/4
Inotiv's CEO is Bob Leasure, appointed in Jan 2019, has a tenure of 7.42 years. total yearly compensation is $2.94M, comprised of 27.5% salary and 72.5% bonuses, including company stock and options. directly owns 2.35% of the company’s shares, worth $41.07K. The average tenure of the management team and the board of directors is 4.9 years and 3.4 years respectively.
Key information
Bob Leasure
Chief executive officer
US$2.9m
Total compensation
| CEO salary percentage | 27.46% |
| CEO tenure | 7.4yrs |
| CEO ownership | 2.4% |
| Management average tenure | 4.9yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Narrative Update • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.
Narrative Update • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Narrative Update • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.Narrative Update • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
Narrative Update • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.Narrative Update • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
Narrative Update • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.Narrative Update • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.Narrative Update • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.Narrative Update • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.Narrative Update • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.Narrative Update • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.New Narrative • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Narrative Update • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).Narrative Update • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.Narrative Update • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).Narrative Update • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).Narrative Update • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.Analysis Article • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...Analysis Article • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Narrative • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.Analysis Article • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...Analysis Article • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...Analysis Article • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...Analysis Article • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...Analysis Article • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...Analysis Article • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$87m |
| Dec 31 2025 | n/a | n/a | -US$69m |
| Sep 30 2025 | US$3m | US$808k | -US$69m |
| Jun 30 2025 | n/a | n/a | -US$79m |
| Mar 31 2025 | n/a | n/a | -US$87m |
| Dec 31 2024 | n/a | n/a | -US$121m |
| Sep 30 2024 | US$2m | US$800k | -US$108m |
| Jun 30 2024 | n/a | n/a | -US$99m |
| Mar 31 2024 | n/a | n/a | -US$71m |
| Dec 31 2023 | n/a | n/a | -US$33m |
| Sep 30 2023 | US$5m | US$787k | -US$105m |
| Jun 30 2023 | n/a | n/a | -US$340m |
| Mar 31 2023 | n/a | n/a | -US$345m |
| Dec 31 2022 | n/a | n/a | -US$341m |
| Sep 30 2022 | US$11m | US$677k | -US$337m |
| Jun 30 2022 | n/a | n/a | -US$83m |
| Mar 31 2022 | n/a | n/a | -US$77m |
| Dec 31 2021 | n/a | n/a | -US$72m |
| Sep 30 2021 | US$1m | US$451k | US$11m |
| Jun 30 2021 | n/a | n/a | -US$279k |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | n/a | n/a | -US$4m |
| Sep 30 2020 | US$770k | US$344k | -US$5m |
| Jun 30 2020 | n/a | n/a | -US$3m |
| Mar 31 2020 | n/a | n/a | -US$2m |
| Dec 31 2019 | n/a | n/a | -US$2m |
| Sep 30 2019 | US$474k | US$191k | -US$790k |
Compensation vs Market: Bob's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD649.92K).
Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.
CEO
Bob Leasure (66 yo)
7.4yrs
Tenure
US$2,941,549
Compensation
Mr. Robert W. Leasure, Jr., also known as Bob, has been President, Chief Executive Officer and Director at Inotiv, Inc. (formerly known as Bioanalytical Systems, Inc.) since joining on January 12, 2019. Fr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$2.94m | 2.35% $ 41.1k | |
| EVP & CFO | 6.3yrs | US$550.27k | 0.22% $ 3.9k | |
| EVP of General Counsel & Corporate Secretary and Chief Compliance Officer | 2.7yrs | US$543.80k | 0.054% $ 950.0 | |
| Chief Strategy Officer & Director | 7.9yrs | US$511.26k | 1.95% $ 34.0k | |
| Chief Commercial Officer | 2yrs | US$473.54k | 1.09% $ 18.9k | |
| VP of Finance | 4.9yrs | no data | no data | |
| Chief Operating Officer of DSA | no data | no data | 0.41% $ 7.1k | |
| Group President of RMS | 4yrs | no data | no data |
4.9yrs
Average Tenure
59yo
Average Age
Experienced Management: NOTV.Q's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$2.94m | 2.35% $ 41.1k | |
| Chief Strategy Officer & Director | 7.9yrs | US$511.26k | 1.95% $ 34.0k | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman | 8.8yrs | US$238.75k | 0.35% $ 6.1k | |
| Independent Director | 4.6yrs | US$187.50k | 0.19% $ 3.3k | |
| Independent Director | 3.4yrs | US$185.00k | 0.51% $ 8.8k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 2.3yrs | US$188.75k | 0.11% $ 1.9k | |
| Independent Director | 2.7yrs | US$197.50k | 0.10% $ 1.7k |
3.4yrs
Average Tenure
63yo
Average Age
Experienced Board: NOTV.Q's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 17:50 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inotiv, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |